Explore

Rapid Read Rapid Read
Advancements in Multiple Sclerosis Diagnosis and Treatment Highlighted at AAN 2026

Advancements in Multiple Sclerosis Diagnosis and Treatment Highlighted at AAN 2026

The landscape of multiple sclerosis (MS) is evolving with significant advancements in diagnosis and treatment, as highlighted at the American Academy of Neurology (AAN) 2026 Annual Meeting. Key developments include the revised 2024 McDonald criteria for earlier diagnosis, the use of biomarkers for monitoring disease progression, and a competitive therapeutic landscape. These changes aim to identify and treat MS earlier in its biological course, potentially improving long-term patient outcomes. Notably, Roche's fenebrutinib showed promising results in Phase III trials, reducing relapse rates and MRI activity in relapsing MS. The meeting also emphasized the importance of biomarker-led monitoring, with real-world use of Octave's MSDA blood test expanding significantly.
Rapid Read Rapid Read
Middle Age Identified as Critical Period for Brain Health Preservation

Middle Age Identified as Critical Period for Brain Health Preservation

Recent research has highlighted the importance of middle age (40-65 years) as a critical period for brain health. Studies show that changes in brain connectivity during this time can influence cognitive decline and dementia risk later in life. Researchers are exploring biomarkers and lifestyle factors that could help identify and mitigate risks during this period, emphasizing the potential for early interventions to preserve cognitive function.
Rapid Read Rapid Read
Joyce A. Cramer Honored with Lifetime Accelerator Award for Advancements in Epilepsy Research

Joyce A. Cramer Honored with Lifetime Accelerator Award for Advancements in Epilepsy Research

Joyce A. Cramer has been awarded the Lifetime Accelerator Award by the Epilepsy Foundation of America for her significant contributions to epilepsy therapy development. Cramer, who has had a distinguished career at Yale University School of Medicine, has been instrumental in advancing clinical research in epilepsy. Her work includes pioneering methods for evaluating drug efficacy and adverse effects, as well as strategies to improve medication compliance. She developed the Quality of Life in Epilepsy Inventory and the Seizure Severity Questionnaire, which have provided more nuanced ways to assess seizure characteristics and the impact of therapies. Cramer also served as President and Chief Scientific Officer of the Epilepsy Therapy Project, where she guided entrepreneurs and pharmaceutical companies in developing innovative treatments. Her efforts have accelerated the translation of scientific ideas into therapeutic opportunities for patients with epilepsy.
Trendline Trendline
Manufacturers Embrace AI to Enhance Quality Amidst Challenges

Manufacturers Embrace AI to Enhance Quality Amidst Challenges

Manufacturers Embrace AI to Enhance Quality Amidst Challenges
Rapid Read Rapid Read
Neurologist Highlights Hopeful Advances in Stroke and Head Injury Recovery

Neurologist Highlights Hopeful Advances in Stroke and Head Injury Recovery

Orlando Swayne, a consultant neurologist, emphasizes the potential for recovery in patients with severe brain injuries through targeted therapy and neuroplasticity. His work at the National Hospital for Neurology and Neurosurgery focuses on the brain's ability to reorganize and form new connections after a stroke or head injury. Swayne's approach challenges the traditional view that brain injuries are irreversible, advocating for early and intensive therapy to maximize recovery. His insights are detailed in his new book, which argues for the importance of providing adequate rehabilitation to improve patients' quality of life.
Reuters Reuters
'It's still working': More are living with cancer as era of targeted drugs takes hold

'It's still working': More are living with cancer as era of targeted drugs takes hold

By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more than 20 years with the help of targeted drugs, drugs that harness the body's immune system, chemotherapy and hormone pills.
Rapid Read Rapid Read
FNIH Honors Dan Doctoroff, Biogen, and NIAMS with Partnership Award

FNIH Honors Dan Doctoroff, Biogen, and NIAMS with Partnership Award

The Foundation for the National Institutes of Health (FNIH) has announced the recipients of the 2026 Charles A. Sanders, MD, Partnership Award. The award will be presented to Dan Doctoroff, founder of Target ALS; Biogen; and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for their contributions to advancing biomedical research. Doctoroff played a key role in the Accelerating Medicines Partnership ALS program, while Biogen has supported FNIH initiatives for 15 years. NIAMS has been instrumental in developing the AMP program, transforming the model for diagnostics and treatments. The award ceremony will take place on October 28, 2026, in Washington, D.C.
Trendline Trendline
Leica Biosystems Expands Collaboration to Develop AI-Powered Diagnostics for Precision Medicine

Leica Biosystems Expands Collaboration to Develop AI-Powered Diagnostics for Precision Medicine

Leica Biosystems Expands Collaboration to Develop AI-Powered Diagnostics for Precision Medicine
Trendline Trendline
IDEAYA and Roche Partner to Develop New Pancreatic Cancer Therapy

IDEAYA and Roche Partner to Develop New Pancreatic Cancer Therapy

IDEAYA and Roche Partner to Develop New Pancreatic Cancer Therapy
Rapid Read Rapid Read
Allen Institute Advances Genetic Therapy for Brain Disorders with New Accelerator

Allen Institute Advances Genetic Therapy for Brain Disorders with New Accelerator

The Allen Institute in Seattle has launched the Brain Health accelerator, a collaborative initiative aimed at developing genetic therapies for brain disorders such as Alzheimer's, Parkinson's, ALS, and Huntington's disease. This effort is part of the broader BRAIN Initiative, a public-private partnership initiated in 2013 to advance brain research and treatment development. The accelerator seeks to translate scientific knowledge about the brain into practical treatments by leveraging genetic therapies, including gene editing. Scientists at the Allen Institute have made significant progress in understanding the genetic underpinnings of brain cells, which is crucial for developing precision therapies. The initiative is attracting researchers like Jeff Carroll, who is focused on Huntington's disease, a condition he has a personal connection to. The accelerator's approach allows for large-scale research efforts that smaller labs cannot achieve alone.
Reuters Reuters
'It's still working': More are living with cancer as era of targeted drugs takes hold

'It's still working': More are living with cancer as era of targeted drugs takes hold

By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more than 20 years with the help of targeted drugs, drugs that harness the body's immune system, chemotherapy and hormone pills.
Rapid Read Rapid Read
Neuroscientists Link Night Shift Work to Brain Volume Losses in Key Areas

Neuroscientists Link Night Shift Work to Brain Volume Losses in Key Areas

A study conducted by neuroscientists in Singapore has revealed that night shift work is associated with brain volume losses in critical areas of the brain. The research, which analyzed MRI and long-term health data from 14,198 middle- to older-age adults, found that among 2,122 shift workers, there was a noticeable pattern of volume loss in the right thalamus and left amygdala. These regions are crucial for memory retrieval and emotional regulation, respectively. The study suggests that these changes may be linked to the disruption of the body's natural circadian rhythm caused by shift work. However, the researchers noted that if shift work is ceased, these reductions in brain volume can be partially recovered within two and a half years.